Regulatory approvals for Epidiolex (purified cannabidiol) in the treatment of childhood drug resistant epilepsy have set a precedent for the use of cannabinoids as a prescribed medicine. Two common reasons cited for the use and prescription of cannabis-based products are pain and insomnia. Unlike drug resistant epilepsy, the level of evidence of efficacy in pain is poorly developed. The lowest quality trials with the greatest methodological shortcomings suggest some benefit, a level of evidence that is inconsistent with widespread prescribing. The evidence in insomnia is scant. Ongoing trial development and critical review of the literature should not be overshadowed by increasing permissiveness towards cannabis use and anecdotal reports of efficacy.

中文翻译：

---

大麻/大麻素的药用应用

Epidiolex（纯化大麻二酚）用于治疗儿童耐药性癫痫的监管批准为使用大麻素作为处方药开创了先例。使用和处方大麻产品的两个常见原因是疼痛和失眠。与耐药性癫痫不同，疼痛疗效的证据水平尚不完善。具有最大方法学缺陷的最低质量试验表明了一些益处，该证据水平与广泛的处方不一致。失眠的证据很少。对大麻使用的日益宽容和关于功效的轶事报告不应使正在进行的试验开发和对文献的批判性审查蒙上阴影。